Rosa-Neto P - Search Results

1

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.

Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium; Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ. Simrén J, et al. Alzheimers Dement. 2021 Jul;17(7):1145-1156. doi: 10.1002/alz.12283. Epub 2021 Jan 25. Alzheimers Dement. 2021. PMID: 33491853 Free PMC article.

2

Early-onset familial Alzheimer's disease (EOFAD).

Wu L, Rosa-Neto P, Hsiung GY, Sadovnick AD, Masellis M, Black SE, Jia J, Gauthier S. Wu L, et al. Can J Neurol Sci. 2012 Jul;39(4):436-45. doi: 10.1017/s0317167100013949. Can J Neurol Sci. 2012. PMID: 22728850 Review.

3

Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.

Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, Fonov V, Jia J, Gauthier S, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative. Wu L, et al. PLoS One. 2012;7(10):e47905. doi: 10.1371/journal.pone.0047905. Epub 2012 Oct 24. PLoS One. 2012. PMID: 23112868 Free PMC article. Clinical Trial.

4

Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.

Gauthier S, Leuzy A, Racine E, Rosa-Neto P. Gauthier S, et al. Prog Neurobiol. 2013 Nov;110:102-13. doi: 10.1016/j.pneurobio.2013.01.003. Epub 2013 Apr 8. Prog Neurobiol. 2013. PMID: 23578568 Review.

5

How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

Gauthier S, Leuzy A, Rosa-Neto P. Gauthier S, et al. Neurodegener Dis. 2014;13(2-3):197-9. doi: 10.1159/000353748. Epub 2013 Aug 7. Neurodegener Dis. 2014. PMID: 23942173 Review.

6

Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.

Leuzy A, Zimmer ER, Bhat V, Rosa-Neto P, Gauthier S. Leuzy A, et al. Int Psychogeriatr. 2014 May;26(5):703-7. doi: 10.1017/S1041610214000118. Epub 2014 Feb 13. Int Psychogeriatr. 2014. PMID: 24524685 No abstract available.

7

In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.

Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P. Zimmer ER, et al. Transl Neurodegener. 2014 Mar 15;3(1):6. doi: 10.1186/2047-9158-3-6. Transl Neurodegener. 2014. PMID: 24628994 Free PMC article.

8

Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.

Leuzy A, Zimmer ER, Heurling K, Rosa-Neto P, Gauthier S. Leuzy A, et al. Amyloid. 2014 Sep;21(3):143-8. doi: 10.3109/13506129.2014.926267. Epub 2014 Jun 11. Amyloid. 2014. PMID: 24919109 Review.

9

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.

Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Zimmer ER, et al. J Neuroinflammation. 2014 Jul 8;11:120. doi: 10.1186/1742-2094-11-120. J Neuroinflammation. 2014. PMID: 25005532 Free PMC article. Review.

10

Developments in Tau PET Imaging.

Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P. Zimmer ER, et al. Can J Neurol Sci. 2014 Sep;41(5):547-53. doi: 10.1017/cjn.2014.15. Can J Neurol Sci. 2014. PMID: 25424608 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

409 results

Search Page